LEHMAN MICHAEL E
CIK: 0001156092
Associated companies
Transaction History
| MTG | ▲ Buy | Grant | 161 | — | 3/5/2025 | View on chart |
| MTG | ▲ Buy | Grant | 4,898 | $125K | 2/5/2025 | View on chart |
| MTG | ▲ Buy | Grant | 128 | — | 11/21/2024 | View on chart |
| MTG | ▲ Buy | Grant | 130 | — | 8/22/2024 | View on chart |
| MTG | ▲ Buy | Grant | 134 | — | 5/21/2024 | View on chart |
| MTG | ▲ Buy | Grant | 139 | — | 3/5/2024 | View on chart |
| MTG | ▲ Buy | Grant | 6,310 | $125K | 2/2/2024 | View on chart |
| MTG | ▲ Buy | Grant | 134 | — | 11/28/2023 | View on chart |
| MTG | ▲ Buy | Grant | 57 | — | 8/24/2023 | View on chart |
| MTG | ▲ Buy | Grant | 61 | — | 8/24/2023 | View on chart |
| MTG | ▲ Buy | Grant | 116 | — | 5/25/2023 | View on chart |
| MTG | ▲ Buy | Grant | 125 | — | 3/2/2023 | View on chart |
| MTG | ▲ Buy | Grant | 8,821 | $125K | 2/3/2023 | View on chart |
| MTG | ▲ Buy | Grant | 61 | — | 11/23/2022 | View on chart |
| MTG | ▲ Buy | Grant | 55 | — | 8/25/2022 | View on chart |
| MTG | ▲ Buy | Grant | 49 | — | 5/26/2022 | View on chart |
| MTG | ▲ Buy | Grant | 45 | — | 3/2/2022 | View on chart |
| MTG | ▲ Buy | Grant | 8,085 | $125K | 2/4/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Barclays Lifts MGIC Target to $29; AM Best Affirms Ratings
Barclays maintained an Equal-Weight rating on MGIC Investment while raising its price target to $29. In related news, AM Best affirmed the credit ratings of the company's operating subsidiaries. These updates provide a neutral backdrop as the stock trades near its 52-week low, with an average analyst target of $31.20.
Barclays Lifts MGIC Target to $29; AM Best Affirms Ratings. Barclays maintained an Equal-Weight rating on MGIC Investment while raising its price target to $29. In related news, AM Best affirmed the credit ratings of the company's operating subsidiaries. These updates provide a neutral backdrop as the stock trades near its 52-week low, with an average analyst target of $31.20.